Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.72 |
| ▸ | RECQL | P46063 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | VNN1 | O95497 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3319140 | 0.87 | HSD17B10 (0.74) | GLAHSD17B10RAB9AVNN1KDM4E | |
| SCHEMBL2995058 | 0.87 | GLA (0.79) | GLAHSD17B10RAB9AVNN1ALDH1A1 | |
| SCHEMBL3319143 | 0.87 | HSD17B10 (0.74) | GLAHSD17B10RAB9AVNN1KDM4E | |
| SCHEMBL2995061 | 0.85 | GLA (0.77) | GLAHSD17B10RAB9AVNN1ALDH1A1 | |
| SCHEMBL5908875 | 0.85 | VNN1 (0.67) | GLAHSD17B10RAB9AVNN1KDM4E | |
| SCHEMBL3315157 | 0.84 | GLA (0.75) | GLAHSD17B10RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL3589879 | 0.84 | GLA (0.75) | GLAHSD17B10RAB9AKDM4EALDH1A1 | |
| SCHEMBL3315160 | 0.84 | GLA (0.75) | GLAHSD17B10RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL5909052 | 0.84 | HSD17B10 (0.63) | GLAHSD17B10RECQLRAB9AVNN1 | |
| SCHEMBL3315881 | 0.84 | GLA (1.00) | GLAHSD17B10RAB9AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060030557-A1 | Substituted pyridines having antiangiogenic activity | HAVIV FORTUNA | 2006-02-09 | — | — | US | disclosed |
| EP-1494672-A1 | AMINOCARBONYL SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, PYRAZINES AND TRIAZINES HAVING ANTIANGIOGENIC ACTIVITY | Abbott Laboratories (US) | 2005-01-12 | — | — | EP | disclosed |
| US-20040014744-A1 | Substituted pyridines having antiangiogenic activity | ABBOTT LABORATORIES | 2004-01-22 | — | — | US | disclosed |
| WO-2003086398-A1 | AMINOCARBONYL SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, PYRAZINES AND TRIAZINES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014744-A1 | Substituted pyridines having antiangiogenic activity | FLT1, FLT4, KDR | GLA 467/4885HSD17B10 2130/4885RECQL 2509/4885 |
| US-20060030557-A1 | Substituted pyridines having antiangiogenic activity | FLT4, KDR, FLT1 | GLA 392/4885HSD17B10 2753/4885RECQL 2243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.